CancerTreatmentInduced Bone Loss CTIBL Clodronate and Bone Mineral Density Hip Bone Mineral Density Substudy ABCSG12 Effect of Zoledronic Acid Percent Change Lumbar Spine Denosumab for CTIBL ID: 716297
Download Presentation The PPT/PDF document "Bone-Targeted Therapy in the Adjuvant B..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Bone-Targeted Therapy in the Adjuvant Breast Cancer SettingSlide2
Cancer-Treatment-Induced Bone Loss (CTIBL)Slide3
Clodronate and Bone Mineral Density (Hip)Slide4
Bone Mineral Density Substudy --ABCSG-12: Effect of Zoledronic AcidPercent Change, Lumbar SpineSlide5
Denosumab for CTIBL (Lumbar Spine)Slide6
Metastatic Niches in Bone MarrowSlide7
Differential Impact of Menopausal StatusSlide8
The "Low Estrogen" HypothesisSlide9
Adjuvant Bisphosphonate Treatment Breast Cancer Recurrence-Postmenopause* Slide10
Conclusions: EBCTCG Meta-AnalysisSlide11
ABCSG-12 Trial DesignSlide12
Adjuvant Denosumab in Breast Cancer (ABCSG-18, Phase 3) Primary Endpoint, First Clinical Fracture Slide13
Adjuvant Denosumab in Breast Cancer (ABCSG-18 Subgroup) Tumor Size > 2 cmSlide14
Bone-Targeting Therapy in Adjuvant Breast Cancer Setting Clinical ConclusionsSlide15
Slide16
ReferencesSlide17
References (cont)Slide18
References (cont)Slide19
Abbreviations